Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives
Kotla N. G., Rana S., Sivaraman G., Sunnapu O., Vemula P. K., Pandit A., Rochev Yu. A.
Advanced Drug Delivery Reviews
Vol.146, P. 248-266
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.addr.2018.06.021
Аннотация:
Oral colon-specific delivery systems emerged as the main therapeutic cargos by making a significant impact in the field of modern medicine for local drug delivery in intestinal inflammation. The site-specific delivery of therapeutics (aminosalicylates, glucocorticoids, biologics) to the ulcerative mucus tissue can provide prominent advantages in mucosal healing (MH). Attaining gut mucosal healing and anti-fibrosis are main treatment outcomes in inflammatory bowel disease (IBD). The pharmaceutical strategies that are commonly used to achieve a colon-specific drug delivery system include time, pH-dependent polymer coating, prodrug, colonic microbiota-activated delivery systems and a combination of these approaches. Amongst the different approaches reported, the use of biodegradable polysaccharide coated systems holds great promise in delivering drugs to the ulcerative regions. The present review focuses on major physiological gastro-intestinal tract challenges involved in altering the ph
Ключевые слова:
Colon-specific drug delivery; Crohn's disease; Inflammatory bowel disease; Microbiota-activated drug delivery; Mucosal healing; Polysaccharides; Prodrug; Ulcerative colitis
Disease control; Diseases; Pathology; Plastic coatings; Polysaccharides; Targeted drug delivery; Colon-specific drug delivery; Crohn's disease; Inflammatory bowel disease; Microbiotas; Mucosal healing; Prodrugs; Ulcerative colitis; Controlled drug delivery; alginic acid; chitosan; dextran; guar gum; hyaluronic acid; pectin; xanthan; polysaccharide; drug delivery system; drug release; enteritis; enzymatic degradation; human; inflammatory bowel disease; intestinal fibrosis; intestine flora; intestine mucosa; intestine transit time; nonhuman; pathophysiology; priority journal; Review; stomach emptying; wound healing; animal; drug effect; inflammation; metabolism; Animals; Drug Delivery Systems; Humans; Inflammation; Intestinal Mucosa; Polysaccharides; Wound Healing
Язык текста: Английский
ISSN: 1872-8294
Kotla N. G.
Rana S.
Sivaraman G.
Sunnapu O.
Vemula P. K.
Pandit A.
Rochev Yu. A. Yurij Alekseevich 1961-
Котла Н. Г.
Рана С.
Сивараман Г.
Суннапу О.
Вемула П. К.
Пандит А.
Рочев Ю. А. Юрий Алексеевич 1961-
Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives
Текст визуальный непосредственный
Advanced Drug Delivery Reviews
Elsevier Science Publisher B.V.
Vol.146 P. 248-266
2019
Обзор
Colon-specific drug delivery Crohn's disease Inflammatory bowel disease Microbiota-activated drug delivery Mucosal healing Polysaccharides Prodrug Ulcerative colitis
Disease control Diseases Pathology Plastic coatings Polysaccharides Targeted drug delivery Colon-specific drug delivery Crohn's disease Inflammatory bowel disease Microbiotas Mucosal healing Prodrugs Ulcerative colitis Controlled drug delivery alginic acid chitosan dextran guar gum hyaluronic acid pectin xanthan polysaccharide drug delivery system drug release enteritis enzymatic degradation human inflammatory bowel disease intestinal fibrosis intestine flora intestine mucosa intestine transit time nonhuman pathophysiology priority journal Review stomach emptying wound healing animal drug effect inflammation metabolism Animals Drug Delivery Systems Humans Inflammation Intestinal Mucosa Polysaccharides Wound Healing
Oral colon-specific delivery systems emerged as the main therapeutic cargos by making a significant impact in the field of modern medicine for local drug delivery in intestinal inflammation. The site-specific delivery of therapeutics (aminosalicylates, glucocorticoids, biologics) to the ulcerative mucus tissue can provide prominent advantages in mucosal healing (MH). Attaining gut mucosal healing and anti-fibrosis are main treatment outcomes in inflammatory bowel disease (IBD). The pharmaceutical strategies that are commonly used to achieve a colon-specific drug delivery system include time, pH-dependent polymer coating, prodrug, colonic microbiota-activated delivery systems and a combination of these approaches. Amongst the different approaches reported, the use of biodegradable polysaccharide coated systems holds great promise in delivering drugs to the ulcerative regions. The present review focuses on major physiological gastro-intestinal tract challenges involved in altering the ph